Richard Buller Biography and Net Worth

Director of Celcuity

Brady Johnson occupies the position of Chief Accounting Officer & VP-Finance at Cidara Therapeutics, Inc.

What is Richard E. Buller's net worth?: The estimated net worth of Richard E. Buller is at least $71,553.51 as of October 23rd, 2024. Mr. Buller owns 6,681 shares of Celcuity stock worth more than $71,554 as of March 7th. This net worth estimate does not reflect any other assets that Mr. Buller may own. Learn More about Richard E. Buller's net worth.
How do I contact Richard E. Buller?: The corporate mailing address for Mr. Buller and other Celcuity executives is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. Celcuity can also be reached via phone at (763) 392-0767. Learn More on Richard E. Buller's contact information.
Has Richard E. Buller been buying or selling shares of Celcuity?: Richard E. Buller has not been actively trading shares of Celcuity during the past quarter. Most recently, Richard E. Buller sold 350 shares of the business's stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $16.25, for a transaction totalling $5,687.50. Following the completion of the sale, the director now directly owns 6,681 shares of the company's stock, valued at $108,566.25. Learn More on Richard E. Buller's trading history.
Are insiders buying or selling shares of Celcuity?: In the last year, insiders at the sold shares 3 times. They sold a total of 1,050 shares worth more than $17,146.50. The most recent insider tranaction occured on October, 23rd when Director Richard E Buller sold 350 shares worth more than $5,687.50. Insiders at Celcuity own 15.8% of the company. Learn More about insider trades at Celcuity.
Information on this page was last updated on 10/23/2024.

Richard E. Buller Insider Trading History at Celcuity

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/23/2024	Sell	350	$16.25	$5,687.50	6,681
6/21/2024	Sell	350	$15.68	$5,488.00	7,381
4/24/2024	Sell	350	$17.06	$5,971.00	7,731
2/21/2024	Sell	350	$14.15	$4,952.50	8,081
12/20/2023	Sell	350	$14.37	$5,029.50	8,431
10/25/2023	Sell	350	$10.23	$3,580.50	8,781
8/30/2023	Sell	350	$9.28	$3,248.00	9,131
8/23/2023	Sell	300	$9.82	$2,946.00	9,481
6/23/2023	Sell	300	$11.79	$3,537.00	9,781
5/22/2023	Sell	100	$10.50	$1,050.00	10,156
5/19/2023	Sell	250	$9.85	$2,462.50	10,256
4/21/2023	Sell	300	$9.70	$2,910.00	8,548
12/19/2022	Sell	300	$11.11	$3,333.00	9,148
10/20/2022	Sell	300	$9.97	$2,991.00	9,448
8/25/2022	Sell	200	$10.05	$2,010.00	9,998
8/19/2022	Sell	300	$8.95	$2,685.00	10,198
6/24/2022	Sell	300	$9.47	$2,841.00	10,498
5/23/2022	Sell	750	$6.24	$4,680.00	10,798
5/19/2022	Sell	250	$5.65	$1,412.50	11,548
4/20/2022	Sell	300	$7.34	$2,202.00	8,525
11/22/2021	Sell	250	$15.54	$3,885.00
11/19/2021	Sell	250	$16.15	$4,037.50

See Full Table

Richard E. Buller Buying and Selling Activity at Celcuity

Celcuity Company Overview

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $10.71

$9.50

$10.71

50 Day Range

MA: $11.84

$8.90

$13.84

2 Week Range

Now: $10.71

$8.53

$22.19

Volume

662,167 shs

Average Volume

264,048 shs

Market Capitalization

$397.66 million

P/E Ratio

N/A

Dividend Yield